## Ramy Youssef Yaacoub

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5674858/publications.pdf

Version: 2024-02-01

68 papers

2,069 citations

236833 25 h-index 243529 44 g-index

70 all docs

70 docs citations

70 times ranked

2632 citing authors

#	Article	IF	CITATIONS
1	Rising occurrence of hypocitraturia and hyperoxaluria associated with increasing prevalence of stone disease in calcium kidney stone formers. Scandinavian Journal of Urology, 2020, 54, 426-430.	0.6	7
2	A California Cancer Registry Analysis of Urothelial and Non-urothelial Bladder Cancer Subtypes: Epidemiology, Treatment, and Survival. Clinical Genitourinary Cancer, 2020, 18, e330-e336.	0.9	12
3	Metabolic diagnoses of recurrent stone formers: temporal, geographic and gender differences. Scandinavian Journal of Urology, 2020, 54, 456-462.	0.6	4
4	Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry. Clinical Genitourinary Cancer, 2019, 17, e995-e1002.	0.9	34
5	Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 478-484.	0.8	11
6	Predictors of Oncologic Outcomes After Treatment of Urothelial Cancer., 2019,, 659-673.		0
7	Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort. World Journal of Urology, 2018, 36, 1835-1843.	1.2	13
8	Antibiotic Utilization Before Endourological Surgery for Urolithiasis: Endourological Society Survey Results. Journal of Endourology, 2018, 32, 978-985.	1.1	12
9	Should metabolic evaluation be performed in patients with struvite stones?. Urolithiasis, 2017, 45, 185-192.	1.2	17
10	Skin-to-tumor Distance Predicts Treatment Failure of T1A Renal Cell Carcinoma Following Percutaneous Cryoablation. Urology, 2017, 108, 195-200.	0.5	4
11	Contemporary Management of Struvite Stones Using Combined Endourologic and Medical Treatment: Predictors of Unfavorable Clinical Outcome. Journal of Endourology, 2016, 30, 771-777.	1.1	24
12	Cost Comparisons Between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses. Journal of Endourology, 2016, 30, S-28-S-33.	1.1	16
13	Radiation Dosimetry for Ureteroscopy Patients: A Phantom Study Comparing the Standard and Obese Patient Models. Journal of Endourology, 2016, 30, 57-62.	1.1	7
14	Digital Tomosynthesis: A Viable Alternative to Noncontrast Computed Tomography for the Follow-Up of Nephrolithiasis?. Journal of Endourology, 2016, 30, 366-370.	1.1	12
15	Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 531.e1-531.e6.	0.8	26
16	Lymphovascular invasion is associated with oncologic outcomes following radical cystectomy for squamous cell carcinoma of the urinary bladder. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 417.e1-417.e8.	0.8	14
17	Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches. Arab Journal of Urology Arab Association of Urology, 2016, 14, 183-191.	0.7	72
18	Prevalence of Hyperoxaluria in Urinary Stone Formers: Chronological and Geographical Trends and a Literature Review. Journal of Endourology, 2016, 30, 469-475.	1.1	13

#	Article	IF	CITATIONS
19	Applications of three-dimensional printing technology in urological practice. BJU International, 2015, 116, 697-702.	1.3	81
20	Redefining the Autonomic Nerve Distribution of the Bladder Using 3-Dimensional Image Reconstruction. Journal of Urology, 2015, 194, 1661-1667.	0.2	34
21	Utility of Biomarkers in the Prediction of Oncologic Outcome after Radical Cystectomy for Squamous Cell Carcinoma. Journal of Urology, 2015, 193, 451-456.	0.2	15
22	Role of fibroblast growth factor in squamous cell carcinoma of the bladder: Prognostic biomarker and potential therapeutic target. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 111.e1-111.e7.	0.8	8
23	Evaluation of Ignition and Burn Risk Associated with Contemporary Fiberoptic and Distal Sensor Endoscopic Technology. Journal of Endourology, 2015, 29, 1076-1082.	1.1	5
24	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. World Journal of Urology, 2015, 33, 1965-1972.	1.2	9
25	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e21-18.e26.	0.8	8
26	Predictors of Oncologic Outcomes After Treatment of Urothelial Cancer., 2015,, 577-591.		1
27	<scp>Ki67</scp> is an independent predictor of oncological outcomes in patients with localized clearâ€ell renal cell carcinoma. BJU International, 2014, 113, 668-673.	1.3	49
28	Clinical Outcomes After Ureteroscopic Lithotripsy in Patients Who Initially Presented with Urosepsis: Matched Pair Comparison with Elective Ureteroscopy. Journal of Endourology, 2014, 28, 1439-1443.	1.1	32
29	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tractâ€"ls There Evidence for Discordant Biology?. Journal of Urology, 2014, 191, 926-931.	0.2	29
30	Squamous cell carcinogenesis and squamous cell carcinoma of the urinary bladder: A contemporary review with focus on nonbilharzial squamous cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 32.e11-32.e16.	0.8	21
31	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2014, 191, 28-34.	0.2	35
32	What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 128-134.	0.8	53
33	Potassium Citrate and Calcium Stones: Benefit or Risk?. , 2014, , 115-130.		O
34	Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2013, 190, 1662-1667.	0.2	23
35	Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus. Journal of Urology, 2013, 190, 452-457.	0.2	25
36	Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma. Urology, 2013, 81, 581-586.	0.5	37

#	Article	IF	Citations
37	Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 676-681.	0.8	4
38	GATA-3 Immunohistochemistry in the Differential Diagnosis of Adenocarcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2013, 37, 1756-1760.	2.1	58
39	Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 614-621.	0.7	10
40	Endoscopy to predict outcomes in upper tract urothelial cancer. Nature Reviews Urology, 2012, 9, 242-243.	1.9	2
41	Editorial Comment. Journal of Urology, 2012, 187, 1711-1712.	0.2	0
42	Evaluation of Vitamin E and Selenium Supplementation for the Prevention of Bladder Cancer in SWOG Coordinated SELECT. Journal of Urology, 2012, 187, 2005-2010.	0.2	41
43	Residual Fragments Following Ureteroscopic Lithotripsy: Incidence and Predictors on Postoperative Computerized Tomography. Journal of Urology, 2012, 188, 2246-2251.	0.2	64
44	Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 273-277.	0.8	29
45	Prognostic markers in renal cell carcinoma: A focus on the â€~mammalian target of rapamycin' pathway. Arab Journal of Urology Arab Association of Urology, 2012, 10, 110-117.	0.7	3
46	Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. European Urology, 2012, 62, e27-e29.	0.9	17
47	Flexible ureterorenoscopy versus extracorporeal shock wave lithotripsy for treatment of lower pole stones of 10–20 mm. BJU International, 2012, 110, 898-902.	1.3	128
48	Prognostic Value of Cyclooxygenase-2 Expression in Squamous Cell Carcinoma of the Bladder. Journal of Urology, 2011, 185, 1112-1117.	0.2	7
49	The role of biopsy in incidental renal tumours. Arab Journal of Urology Arab Association of Urology, 2011, 9, 11-14.	0.7	2
50	Prostate sparing cystectomy: A procedure with limited indications. Arab Journal of Urology Arab Association of Urology, 2011, 9, 113-114.	0.7	0
51	Expression of cell cycle–related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladderâ⁻†. Human Pathology, 2011, 42, 347-355.	1.1	22
52	Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. Urology, 2011, 77, 861-866.	0.5	31
53	Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer. Scientific World Journal, The, 2011, 11, 369-381.	0.8	72
54	Lymphadenectomy in Management of Invasive Bladder Cancer. International Journal of Surgical Oncology, 2011, 2011, 1-9.	0.3	19

#	Article	IF	CITATIONS
55	Upper urinary tract urothelial carcinoma with locoâ€regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU International, 2011, 108, 1286-1291.	1.3	71
56	The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus. European Urology, 2011, 59, 912-918.	0.9	167
57	Primary Adenocarcinoma of the Urinary Bladder. American Journal of Clinical Pathology, 2011, 135, 822-830.	0.4	21
58	The Impact of Previous Ureteroscopic Tumor Ablation on Oncologic Outcomes After Radical Nephrouretectomy for Upper Urinary Tract Urothelial Carcinoma. Journal of Endourology, 2011, 25, 775-779.	1.1	21
59	Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2010, 184, 453-458.	0.2	182
60	Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers. Journal of Urology, 2010, 183, 1744-1750.	0.2	91
61	Molecular targets and targeted therapies in bladder cancer management. World Journal of Urology, 2009, 27, 9-20.	1.2	37
62	Shock Wave Lithotripsy Versus Semirigid Ureteroscopy for Proximal Ureteral Calculi (<20 mm): A Comparative Matched-pair Study. Urology, 2009, 73, 1184-1187.	0.5	33
63	Semirigid Ureteroscopy for Ureteral Stones: A Multivariate Analysis of Unfavorable Results. Journal of Urology, 2009, 181, 1158-1162.	0.2	89
64	Long-Term Effects of Extracorporeal Shock Wave Lithotripsy on Renal Function: Our Experience With 156 Patients With Solitary Kidney. Journal of Urology, 2008, 179, 2229-2232.	0.2	39
65	Anatomic Predictors of Formation of Lower Caliceal Calculi: Is It the Time for Three-Dimensional Computed Tomography Urography?. Journal of Endourology, 2008, 22, 2175-2180.	1.1	9
66	Does Degree of Hydronephrosis Affect Success of Extracorporeal Shock Wave Lithotripsy for Distal Ureteral Stones?. Urology, 2007, 69, 431-435.	0.5	15
67	Impact of the degree of hydronephrosis on the efficacy of in situ extracorporeal shock-wave lithotripsy for proximal ureteral calculi. Scandinavian Journal of Urology and Nephrology, 2007, 41, 208-213.	1.4	22
68	Clinical Outcomes After Ureteroscopic Lithotripsy in Patients Who Initially Presented with Urosepsis: Matched Pair Comparison with Elective Ureteroscopy. Journal of Endourology, 0, , 150127063131006.	1.1	0